Tickernomics

10y

Historical Returns*:

SPY

27.80%

-5.34%

ATRA

SPY

32.66%

-96.99%

ATRA

SPY

108.59%

-96.86%

ATRA

SPY

302.52%

-98.10%

ATRA

*Assumes dividends reinvested

Market Stats:

Market Capitalization($MM)

Enterprise Value($MM)

Daily Volume(MM)

91.09

72.79

0.11

Valuation Metrics:

Price/Earnings Ratio

Price/Sales Ratio

Price/Book Value

FCF Yield(%)

Dividend Yield(%)

EV/EBITDA

-0.13

0.91

-1.01

-156.32

0.00

-0.82

Profitability Stats:

Operating Margin %(ttm)

Gross Profit %(ttm)

EBITDA Margin %(ttm)

-54.14

81.08

-65.31

Shareholder Value Creation:

Cost of Capital %(est)

ROIC %(ttm)

ROCE %(ttm)

Beta

8.5152

-274.05

-57.98

1.14

Other Earnings and Cash Flow Stats:

Atara Biotherapeutics Inc. ( ATRA ) Net Income TTM ($MM) is -677.21

Atara Biotherapeutics Inc. ( ATRA ) Operating Income TTM ($MM) is -124.51

Atara Biotherapeutics Inc. ( ATRA ) Owners' Earnings Annual ($MM) is 0.00

Atara Biotherapeutics Inc. ( ATRA ) Current Price to Owners' Earnings ratio is 0.00

Atara Biotherapeutics Inc. ( ATRA ) EBITDA TTM ($MM) is -119.99

Atara Biotherapeutics Inc. ( ATRA ) EBITDA Margin is -65.31%

Capital Allocation:

Atara Biotherapeutics Inc. ( ATRA ) has paid 0.00 dividends per share and bought back 35.4504 million shares in the past 12 months

Atara Biotherapeutics Inc. ( ATRA ) has reduced its debt by 12.022 million USD in the last 12 months

Capital Structure:

Atara Biotherapeutics Inc. ( ATRA ) Interest-bearing Debt ($MM) as of last quarter is 48

Atara Biotherapeutics Inc. ( ATRA ) Annual Working Capital Investments ($MM) are 5

Atara Biotherapeutics Inc. ( ATRA ) Book Value ($MM) as of last quarter is -91

Atara Biotherapeutics Inc. ( ATRA ) Debt/Capital as of last quarter is -54%

Other Balance Sheet Stats:

Atara Biotherapeutics Inc. ( ATRA ) has 46 million in cash on hand as of last quarter

Atara Biotherapeutics Inc. ( ATRA ) has 155 million of liabilities due within 12 months, and long term debt 0 as of last quarter

Atara Biotherapeutics Inc. ( ATRA ) has 7 common shares outstanding as of last quarter

Atara Biotherapeutics Inc. ( ATRA ) has 0 million USD of preferred stock value

Academic Scores:

Atara Biotherapeutics Inc. ( ATRA ) Altman Z-Score is -21.53 as of last quarter

Atara Biotherapeutics Inc. ( ATRA ) Piotroski Score is 5.00 as of last quarter

Corporate Governance:

Atara Biotherapeutics Inc. ( ATRA ) largest shareholder is owning shares at 0.00 ($MM) value

Henrich Jill(an insider) Sold 1000 shares of Atara Biotherapeutics Inc. ( ATRA ) for the amount of $11198.00 on 2024-11-18

22.15% of Atara Biotherapeutics Inc. ( ATRA ) is held by insiders, and 50.82% is held by institutions

Atara Biotherapeutics Inc. ( ATRA ) went public on 2014-10-16

About Atara Biotherapeutics Inc. ( ATRA ) :

Atara Biotherapeutics, Inc. develops therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma. Its CAR T immunotherapy pipeline products include ATA2271 and ATA3271 to treat mesothelin; and ATA3219 for the treatment of B-cell malignancies, as well as ATA188 that is in Phase 2 clinical trials to treat multiple sclerosis. Atara Biotherapeutics, Inc. has a license agreement with Memorial Sloan Kettering Cancer Center; license, and research and development collaboration agreement with QIMR Berghofer Medical Research Institute; and strategic collaboration with H. Lee Moffitt Cancer Center. The company was incorporated in 2012 and is headquartered in Thousand Oaks, California.

DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.